Why is Vertex Pharmaceuticals stock down 8% over the last 5 days?
The stock price of Vertex Pharmaceuticals (NASDAQ: VRTX) has seen an 8.1% drop over the last five trading days, after the company announced that it will discontinue the clinical trials for VX-864, an experimental treatment for the rare genetic disorder alpha-1 antitrypsin (AATD).
Should you hold vertex (verx) stock?
The consensus among Wall Street analysts is that investors should "hold" Vertex stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VERX, but not buy additional shares or sell existing shares. View analyst ratings for Vertex or view top-rated stocks.
When is vertex's next quarterly earnings release?
Vertex is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022. View our earnings forecast for Vertex. How were Vertex's earnings last quarter?
Is vertex a profitable company?
Vertex has a market capitalization of $2.46 billion and generates $374.67 million in revenue each year. The company earns $-78.94 million in net income (profit) each year or ($0.01) on an earnings per share basis. How many employees does Vertex have?
Why is the vertex falling?
Vertex Pharmaceuticals in Boston, Massachusetts.
Is Vertex Pharmaceuticals A Good Investment?
In this defensive sector, Vertex Pharmaceuticals Incorporated VRTX is a good stock to own. There are several reasons to own the stock. Good Rank and Rising Estimates: Vertex has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Will Vertex stock recover?
Based on our forecasts, a long-term increase is expected, the "VRTX" stock price prognosis for 2027-06-04 is 343.182 USD. With a 5-year investment, the revenue is expected to be around +25.4%. Your current $100 investment may be up to $125.4 in 2027. Get It Now!
What happened VRTX stock?
Vertex Pharmaceuticals (NASDAQ:VRTX) has recorded the biggest intraday loss in nearly 11 months on Monday, even after several Wall Street analysts urged investors to buy the stock on the dip following an FDA-imposed clinical hold on a study for the diabetes candidate, VX-880.
Is Vertex a buy or sell?
Vertex Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 9 buy ratings, 7 hold ratings, and no sell ratings.
Should I sell VRTX stock?
Out of 15 analysts, 6 (40%) are recommending VRTX as a Strong Buy, 2 (13.33%) are recommending VRTX as a Buy, 6 (40%) are recommending VRTX as a Hold, 1 (6.67%) are recommending VRTX as a Sell, and 0 (0%) are recommending VRTX as a Strong Sell. What is VRTX's earnings growth forecast for 2022-2024?
Is Vertex overvalued?
Price to Book Ratio PB vs Industry: VRTX is overvalued based on its Price-To-Book Ratio (6x) compared to the US Biotechs industry average (1.6x).
Will Vertex Energy stock go up?
The 4 analysts offering 12-month price forecasts for Vertex Energy Inc have a median target of 22.50, with a high estimate of 25.00 and a low estimate of 20.00. The median estimate represents a +52.23% increase from the last price of 14.78.
Is Vertex a buy Zacks?
Vertex Pharmaceuticals Incorporated - Hold Zacks' proprietary data indicates that Vertex Pharmaceuticals Incorporated is currently rated as a Zacks Rank 3 and we are expecting an inline return from the VRTX shares relative to the market in the next few months.
Why did Vertex drop in October?
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) fell 23.4% in October, according to data from S&P Global Market Intelligence after the biotech discontinued development of a drug for alpha-1 antitrypsin deficiency (AATD).
Is Vertex Pharmaceuticals a good place to work?
90% of employees at Vertex Pharmaceuticals Inc say it is a great place to work compared to 57% of employees at a typical U.S.-based company. Source: Great Place to Work® 2021 Global Employee Engagement Study.
What is VRTX?
Dell PowerEdge VRTX is a computer hardware product line from Dell. It is a mini-blade chassis with built-in storage system. The VRTX comes in two models: a 19" rack version that is 5 rack units high or as a stand-alone tower system.
Why did Vertex nix the VX-864?
Is Vertex a failure?
Vertex is reportedly nixing the program after VX-864 failed to show a clear-cut clinical benefit in a midstage trial. Last year, the biotech dropped another AATD clinical candidate, known as VX-814, over safety concerns.
Is Vertex a candidate for AATD?
Of broader concern, though, is Vertex's failure to develop an in-house drug for a disease other than cystic fibrosis. That appears to be the main driver behind today's double-digit sell-off.
When is the earnings conference call for Vertex?
Last year, the biotech dropped another AATD clinical candidate, known as VX-814, over safety concerns. As a result Vertex no longer has a candidate in its clinical pipeline for this potentially lucrative genetic disorder.
Is Vertex a hold stock?
How can I listen to Vertex's earnings call? Vertex will be holding an earnings conference call on Wednesday, August 11th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13721451".
